Michael J Burdick

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44113, USA
    Int J Radiat Oncol Biol Phys 73:1439-45. 2009
  2. doi request reprint Marginal recurrence requiring salvage radiotherapy after stereotactic body radiotherapy for spinal metastases
    Shlomo A Koyfman
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
    Int J Radiat Oncol Biol Phys 83:297-302. 2012
  3. doi request reprint Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 78:1033-9. 2010
  4. doi request reprint External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma
    Michael J Burdick
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 79:1124-30. 2011

Detail Information

Publications4

  1. doi request reprint Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44113, USA
    Int J Radiat Oncol Biol Phys 73:1439-45. 2009
    ..Most of the present data regarding the PG of GS7 CaP refer to surgical specimens. Our goal was to determine whether the biopsy GS used at the time of medical decision making predicted for the biochemical outcome...
  2. doi request reprint Marginal recurrence requiring salvage radiotherapy after stereotactic body radiotherapy for spinal metastases
    Shlomo A Koyfman
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
    Int J Radiat Oncol Biol Phys 83:297-302. 2012
    ..We sought to quantify and identify risk factors associated with margin recurrence (MR) requiring salvage radiotherapy after stereotactic body radiation therapy (SBRT) for spinal metastases...
  3. doi request reprint Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 78:1033-9. 2010
    ....
  4. doi request reprint External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma
    Michael J Burdick
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 79:1124-30. 2011
    ..We combined external beam radiotherapy (EBRT) with yttrium-90 ibritumomab tiuxetan ((90)Y-IT) in an attempt to improve therapeutic response in patients with relapsed or refractory bulky follicular lymphoma (RRBFL)...